Elsevier

Microbial Pathogenesis

Volume 17, Issue 2, August 1994, Pages 111-120
Microbial Pathogenesis

Regular Article
The fibronectin binding domain of the Sfb protein adhesin of Streptococcus pyogenes occurs in many group A streptococci and does not cross-react with heart myosin

https://doi.org/10.1006/mpat.1994.1057Get rights and content

Abstract

Sfb protein, a fibronectin binding adhesin of Streptococcus pyogenes (Lancefield group A streptococcus), mediates streptococcal adherence to human epithelial cells via its fibronectin binding domain coded by a repetitive gene region named fnbr. In the present study, Southern blot analysis using the fnbr gene region as a probe to screen genomic DNA from 51 epidemiologically unrelated clinical isolates of S. pyogenes revealed that 70% carried a sequence homologous to the fnbr probe. Among ten other streptococcal strains belonging to serological groups B, C, and G, DNA from only two human S. equisimilis (group C) strains reacted with the probe. Further analysis by PCR-mediated amplification of the binding repeat coding sequences revealed that repeats of different S. pyogenes isolates were identical in size but varied in number, ranging from one to five. Most of the isolates were shown to carry multiple repeats. Presence of the probe-positive sequence correlated strongly with streptococcal binding to purified fibronectin and adherence to HEp2 human epithelial cells; of the 36 probe-positive isolates, 95% bound fibronectin and 89% adhered strongly to epithelial cells, whereas among the 15 probe-negative isolates only 27% had binding actvities for fibronectin and 27% showed strong adherence to HEp2 cells. Antibodies raised against the fibronectin binding domain of Sfb protein recognized streptococcal fibronectin binding surface proteins in most of the clinical isolates but did not react with heart or skeletal muscle myosin in an enzyme immunoassay, as is the case with antibodies directed to M protein, another major surface protein of group A streptococci. The results of the present study suggest that Sfb protein could be a potential candidate for a streptococcal vaccine.

References (0)

Cited by (49)

  • Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection

    2017, Nanomedicine: Nanotechnology, Biology, and Medicine
    Citation Excerpt :

    Hence, mice immunized with J14-dT co-administered with CTB as adjuvant showed 70% survival when challenged with a homologous GAS M1 strain, whereas the protection level of J14-specific antibodies against heterologous strains was slightly reduced compared to J14 sequence variants.15 In contrast, the sequences encompassed by the FNBR peptides seem to be almost 100% conserved.16,18,48,60 This strongly argues for the bivalent vaccine formulation.

  • Streptococcus Group A Vaccines

    2017, Plotkin's Vaccines
  • Streptococcus group A vaccines

    2012, Vaccines: Sixth Edition
  • Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation

    2007, Vaccine
    Citation Excerpt :

    Apart from the M protein, other S. pyogenes antigens have been considered as vaccine candidates, such as fibronectin-binding proteins, including fibronectin-binding protein I (SfbI) [18–20], which plays a major role in bacterial attachment, colonisation and invasion [15–17,33–39], and impairs host clearance mechanisms by interacting with IgG [40,41]. The functional domains of the SfbI protein are highly conserved and it is expressed by a large number of clinical isolates from patients affected with different forms of disease, who live in different geographic areas [42,43]. Therefore, the SfbI protein is an ideal candidate to target in a multi-component vaccine formulation.

View all citing articles on Scopus
View full text